Addiction, Health, Behaviour Change | CGL

CGL statement on the discontinuation of BritLofex (lofexidine hydrochloride)

CGL statement on the discontinuation of BritLofex (lofexidine hydrochloride)

14 March 2018

We have been informed that BritLofex (lofexidine hydrochloride), the opioid detoxification medication, has been temporarily discontinued.

BritLofex is used to reduce or prevent withdrawal symptoms such as chills, sweating, stomach cramps, muscle pain, difficulties sleeping and runny nose.

In the absence of BritLofex we will be recommending:

  1. Detoxification with licensed medications, buprenorphine or methadone
  2. Optimising the use of symptomatic relief medication

We have begun conversations with Public Health England regarding this matter, as well as commissioners and colleagues in Collective Voice to establish safe and effective solutions for service users. 

We are keen to share best practice with other affected organisations, so please keep an eye on this page for updates. 

Update: clinical guidance for managing the current Lofexidine shortage

We are currently in the process of establishing when, or if, Lofexidine supplies will be available again. To help manage the current situation we, together with DISC, have agreed and published clinical advice for the management of opioid withdrawal in our services across the country.

Please click the links below to access the clinical advice as well as additional supporting documents.